You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
7 September 2026 - Chinese biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) announced on Sunday positive preliminary data from a Phase 2 clinical trial in older adults in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + ...
7 September 2026 - Rznomics Inc (KOSDAQ: 476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, on Monday announced a breakthrough in the high-efficiency production of circular RNA (circRNA...
4 September 2026 - Australian biopharmaceutical company Immuron Limited (ASX: IMC; NASDAQ: IMRN), which develops and commercialises targeted polyclonal antibodies for infectious diseases, announced on Friday that it has signed an exclusive US distrib...
4 September 2026 - Invagen Pharmaceuticals Inc, a wholly owned subsidiary of India-based pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA), announced on Thursday that it has entered into a strategic partnership with China-based Qilu Pharm...
4 September 2026 - Molecular diagnostics company Cepheid, a Danaher (NYSE:DHR) company, announced on Thursday that it has received Emergency Use Listing (EUL) from the World Health Organization (WHO) for the Xpert Hemorrhagic Fever Panel test to supp...
4 September 2026 - Kali Therapeutics, a clinical-stage biotechnology company focused on new therapies for autoimmune and inflammatory diseases, announced on Thursday that the US Food and Drug Administration (FDA) has cleared the company's Invest...
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royalty-bearing patent and know-how licence agreement w...